SAN DIEGO, Oct. 31, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the commercial launch of the Fantom Encore bioresorbable scaffold (“BRS”) and the first implant of Fantom Encore in the FANTOM Post Market Trial. […]
Other News
Abiomed Announces Q2 FY 2019 Record Revenue of $182 Million, up 37% Over Prior Year
DANVERS, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported second quarter fiscal 2019 revenue of $181.8 million, an increase of 37% compared to revenue of $132.8 million for the same period of fiscal 2018. Second quarter fiscal […]
Janssen Shows Commitment to Advancing the Science and Treatment of Blood Cancers and Related Conditions With More Than 80 ASH 2018 Data Presentations From Differentiated Oncology and Cardiovascular Portfolios
RARITAN, N.J., Nov. 1, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 46 company-sponsored and more than 37 investigator-led abstracts will be presented at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, CA on December 1-4. Highlights include eight company-sponsored oral presentations, including data for the Bruton’s tyrosine kinase (BTK) […]
CryoLife Reports Third Quarter 2018 Results
ATLANTA, Oct. 31, 2018 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the third quarter ended September 30, 2018. Third Quarter and Recent Business Highlights: Total revenues increased 47 percent to $64.6 million in the third quarter of 2018 compared to the […]
Osprey Medical Announces Capital Raising of US$14.5M to Accelerate US and International Growth
MINNEAPOLIS–(BUSINESS WIRE)–Minnesota-based Osprey Medical Inc. (ASX:OSP) (Osprey or Company) today announces that it has entered into an agreement with Allan Gray, a leading investment management firm, to subscribe for approximately 64.5m CHESS Depositary Interests (CDIs) in the Company (representing approximately 32.3m shares of common stock) through the Australian Securities Exchange (ASX) at […]
Teleflex Reports Third Quarter 2018 Results
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 30, 2018. Third quarter 2018 net revenues were $609.7 million, an increase of 14.0% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, third quarter 2018 […]
Corindus to Report Third Quarter Financial Results on November 6, 2018
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the third quarter of 2018 on Tuesday, November 6, 2018 after the close of the U.S. financial markets. Mark Toland, President and Chief […]
Teleflex to Present at the Credit Suisse 27th Annual Healthcare Conference
WAYNE, Pa.–(BUSINESS WIRE)–Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Credit Suisse 27th Annual Healthcare Conference at The Phoenician in Scottsdale, AZ, Wednesday, November 14, 2018 at 11:30 a.m. (MST). A live audio webcast of the conference presentation, along with the accompanying slide presentation, […]
Cardiovascular Systems, Inc. Reports Fiscal 2019 First-Quarter Financial Results
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal first quarter, ended September 30, 2018. CSI’s first-quarter revenues were $56.3 million, an increase of $6.6 million, […]
Novoheart to Generate USD $1.7m From Strategic Partnership to Build Good Manufacturing Practice Facility to Create Clinical-Grade Human Stem Cell Libraries
VANCOUVER, British Columbia, Oct. 31, 2018 (GLOBE NEWSWIRE) — Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce that it has entered into a service agreement with Xellera Therapeutics Limited, representing Phase 1 of an intended long-term strategic partnership between the companies. […]



